Estudo observacional sugere que a coprescrição de inibidores da fosfodiesterase tipo 5 (p. e., sildenafila) e nitratos orais não está associada a risco aumentado de desfechos cardiovasculares adversos em homens com doença cardíaca isquêmica.

Adverse Events Associated With Coprescription of Phosphodiesterase Type 5 Inhibitors and Oral Organic Nitrates in Male Patients With Ischemic Heart Disease: A Case-Crossover Study – Annals of Internal Medicine

Comentários:

PDE5 inhibitors didn’t increase cardiovascular events in men on nitrates for heart disease – ACP Internist

PDE5 Inhibitors Prescribed for Men on Oral Nitrates for IHD – HealthDay